Lipoprotein (a) As a Biomarker for Cardiovascular Diseases and Potential New Therapies to Mitigate Risk

Overview

Journal Curr Vasc Pharmacol

Publisher Bentham Science Publishers

Date 2023 Dec 23

PMID 38141196

Authors

Debabrata Mukherjee

Steven E Nissen

Affiliations

Soon will be listed here.

Abstract

Background: Lipoprotein (a) [Lp(a)] is a molecule that induces inflammation of the blood vessels, atherogenesis, valvular calcification, and thrombosis.

Methods: We review the available evidence that suggests that high Lp(a) levels are associated with a persisting risk for atherosclerotic cardiovascular diseases despite optimization of established risk factors, including low-density lipoprotein cholesterol (LDL-C) levels.

Observations: Approximately a quarter of the world population have Lp(a) levels of >50 mg/dL (125 nmol/L), a level associated with elevated cardiovascular risk. Lifestyle modification, statins, and ezetimibe do not effectively lower Lp(a) levels, while proprotein convertase subtilisin/kexin type 9 (PCSK-9) inhibitors and niacin only lower Lp(a) levels modestly. We describe clinical studies suggesting that gene silencing therapeutics, such as small interfering RNA (siRNA) and antisense oligonucleotide targeting Lp(a), offer a targeted approach with the potential for safe and robust Lp(a)- lowering with only a few doses (3-4) per year. Prospective randomized phase 3 studies are ongoing to validate safety, effectiveness in improving hard clinical outcomes, and tolerability to assess these therapies.

Conclusion: Several emerging treatments with robust Lp(a)-lowering effects may significantly lower atherosclerotic cardiovascular risk.

Citing Articles

Increasing provider awareness of Lp(a) testing for patients at risk for cardiovascular disease: A comparative study.

Eid W, Sapp E, Conroy C, Bessinger C, Moody C, Yadav R Am J Prev Cardiol. 2024; 21:100895.

PMID: 39720768 PMC: 11666892. DOI: 10.1016/j.ajpc.2024.100895.

The Effects of Red Palm Oil, Koja Bay Leaves, and Passion Fruit Seeds Formulation on Antioxidant Activity, Antihyperlipidemia, BDNF, and Lipase Enzyme Activity on Sprague-Dawley Rats.

Sari D, Ibrahim N, Herlina N, Arrasyid N, Dharmajaya R, Rachmawati M J Exp Pharmacol. 2024; 16:271-284.

PMID: 39262571 PMC: 11389710. DOI: 10.2147/JEP.S466494.

Statins and Venous Thromboembolic Disease - Where are we Now?.

Poredos P, Mukherjee D, Blinc A Curr Vasc Pharmacol. 2024; 22(4):297-300.

PMID: 38441024 DOI: 10.2174/0115701611308323240229050237.

References

Lau F, Giugliano R . Lipoprotein(a) and its Significance in Cardiovascular Disease: A Review. JAMA Cardiol. 2022; 7(7):760-769. DOI: 10.1001/jamacardio.2022.0987. View

Maranhao R, Carvalho P, Strunz C, Pileggi F . Lipoprotein (a): structure, pathophysiology and clinical implications. Arq Bras Cardiol. 2014; 103(1):76-84. PMC: 4126764. DOI: 10.5935/abc.20140101. View

Saleheen D, Haycock P, Zhao W, Rasheed A, Taleb A, Imran A . Apolipoprotein(a) isoform size, lipoprotein(a) concentration, and coronary artery disease: a mendelian randomisation analysis. Lancet Diabetes Endocrinol. 2017; 5(7):524-533. PMC: 5483508. DOI: 10.1016/S2213-8587(17)30088-8. View

Tada H, Takamura M, Kawashiri M . Lipoprotein(a) as an Old and New Causal Risk Factor of Atherosclerotic Cardiovascular Disease. J Atheroscler Thromb. 2019; 26(7):583-591. PMC: 6629747. DOI: 10.5551/jat.RV17034. View

Coassin S, Erhart G, Weissensteiner H, Eca Guimaraes de Araujo M, Lamina C, Schonherr S . A novel but frequent variant in LPA KIV-2 is associated with a pronounced Lp(a) and cardiovascular risk reduction. Eur Heart J. 2017; 38(23):1823-1831. PMC: 5837733. DOI: 10.1093/eurheartj/ehx174. View

Langsted A, Nordestgaard B, Kamstrup P . Elevated Lipoprotein(a) and Risk of Ischemic Stroke. J Am Coll Cardiol. 2019; 74(1):54-66. DOI: 10.1016/j.jacc.2019.03.524. View

Arora P, Kalra R, Callas P, Alexander K, Zakai N, Wadley V . Lipoprotein(a) and Risk of Ischemic Stroke in the REGARDS Study. Arterioscler Thromb Vasc Biol. 2019; 39(4):810-818. PMC: 6511401. DOI: 10.1161/ATVBAHA.118.311857. View

Fu H, Zhang D, Zhu R, Cui L, Qiu L, Lin S . Association between lipoprotein(a) concentration and the risk of stroke in the Chinese Han population: a retrospective case-control study. Ann Transl Med. 2020; 8(5):212. PMC: 7154407. DOI: 10.21037/atm.2020.01.38. View

Aronis K, Zhao D, Hoogeveen R, Alonso A, Ballantyne C, Guallar E . Associations of Lipoprotein(a) Levels With Incident Atrial Fibrillation and Ischemic Stroke: The ARIC (Atherosclerosis Risk in Communities) Study. J Am Heart Assoc. 2017; 6(12). PMC: 5779047. DOI: 10.1161/JAHA.117.007372. View

10.

Pan Y, Li H, Wang Y, Meng X, Wang Y . Causal Effect of Lp(a) [Lipoprotein(a)] Level on Ischemic Stroke and Alzheimer Disease: A Mendelian Randomization Study. Stroke. 2019; 50(12):3532-3539. DOI: 10.1161/STROKEAHA.119.026872. View

11.

Kosmas C, Silverio D, Sourlas A, Peralta R, Montan P, Guzman E . Role of lipoprotein (a) in peripheral arterial disease. Ann Transl Med. 2019; 7(Suppl 6):S242. PMC: 6789348. DOI: 10.21037/atm.2019.08.77. View

12.

Golledge J, Rowbotham S, Velu R, Quigley F, Jenkins J, Bourke M . Association of Serum Lipoprotein (a) With the Requirement for a Peripheral Artery Operation and the Incidence of Major Adverse Cardiovascular Events in People With Peripheral Artery Disease. J Am Heart Assoc. 2020; 9(6):e015355. PMC: 7335512. DOI: 10.1161/JAHA.119.015355. View

13.

Madsen C, Kamstrup P, Langsted A, Varbo A, Nordestgaard B . Lipoprotein(a)-Lowering by 50 mg/dL (105 nmol/L) May Be Needed to Reduce Cardiovascular Disease 20% in Secondary Prevention: A Population-Based Study. Arterioscler Thromb Vasc Biol. 2019; 40(1):255-266. DOI: 10.1161/ATVBAHA.119.312951. View

14.

Liu T, Yoon W, Lee S . Recent Updates of Lipoprotein(a) and Cardiovascular Disease. Chonnam Med J. 2021; 57(1):36-43. PMC: 7840349. DOI: 10.4068/cmj.2021.57.1.36. View

15.

Zheng K, Tsimikas S, Pawade T, Kroon J, Jenkins W, Doris M . Lipoprotein(a) and Oxidized Phospholipids Promote Valve Calcification in Patients With Aortic Stenosis. J Am Coll Cardiol. 2019; 73(17):2150-2162. PMC: 6494952. DOI: 10.1016/j.jacc.2019.01.070. View

16.

Vassiliou V, Flynn P, Raphael C, Newsome S, Khan T, Ali A . Lipoprotein(a) in patients with aortic stenosis: Insights from cardiovascular magnetic resonance. PLoS One. 2017; 12(7):e0181077. PMC: 5509300. DOI: 10.1371/journal.pone.0181077. View

17.

Thanassoulis G, Campbell C, Owens D, Smith J, Smith A, Peloso G . Genetic associations with valvular calcification and aortic stenosis. N Engl J Med. 2013; 368(6):503-12. PMC: 3766627. DOI: 10.1056/NEJMoa1109034. View

18.

Patel A, Wang M, Pirruccello J, Ellinor P, Ng K, Kathiresan S . Lp(a) (Lipoprotein[a]) Concentrations and Incident Atherosclerotic Cardiovascular Disease: New Insights From a Large National Biobank. Arterioscler Thromb Vasc Biol. 2020; 41(1):465-474. PMC: 7769893. DOI: 10.1161/ATVBAHA.120.315291. View

19.

Jawi M, Frohlich J, Chan S . Lipoprotein(a) the Insurgent: A New Insight into the Structure, Function, Metabolism, Pathogenicity, and Medications Affecting Lipoprotein(a) Molecule. J Lipids. 2020; 2020:3491764. PMC: 7016456. DOI: 10.1155/2020/3491764. View

20.

Nissen S, Wolski K, Cho L, Nicholls S, Kastelein J, Leitersdorf E . Lipoprotein(a) levels in a global population with established atherosclerotic cardiovascular disease. Open Heart. 2022; 9(2). PMC: 9577925. DOI: 10.1136/openhrt-2022-002060. View